New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-brain barrier are being developed. In addition, a new type of drug for MS is making its debut. This part of trend insights on life science 2025 is about neurology.
The progress in Alzheimer's cannot possibly have gone unnoticed by anyone in the industry. Especially not in Sweden, as Swedish BioArctic are pioneers in the field. In November, the company's drug Leqembi (lecanemab) received a nod from the European Medicines Agency's scientific committee CHMP.
But Leqembi has not yet been formally approved in Europe. The European Commission has asked CHMP to consider two additional questions that will be discussed in the committee’s meeting in February and then the decision will be taken.
News in English
